Revised SPC: Imfinzi (durvalumab) 50 mg/mL concentrate for solution for infusion

The following immune-related adverse reactions have been observed in patients treated with monotherapy: meningitis (rare), encephalitis and Guillain-Barre syndrome (both frequency unknown).

electronic Medicines compendium